Adaptive Biotechnologies Corporation (ADPT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

16/25

Growth 5 Margin 1 Expansion 4 Platform 4 Financial 2

latest quarter score

Earnings Reports

16
Adaptive Biotechnologies (ADPT) Q2 2026: Serial Testing Pull-Through Rises to 75%, Unlocking MRD Upside
July 30, 2026
23
Adaptive Biotechnologies (ADPT) Q4 2025: MRD Revenue Jumps 46% as ASP and Volume Tailwinds Strengthen
June 15, 2026
21
Adaptive Biotechnologies (ADPT) Q1 2026: MRD Revenue Jumps 53% as Community and Blood-Based Testing Hit Milestones
May 06, 2026
24
Adaptive Biotechnologies (ADPT) Q3 2025: MRD Revenue Jumps 52% as Clinical Volume and ASPs Accelerate
November 06, 2025
22
Adaptive Biotechnologies (ADPT) Q2 2025: MRD Revenue Jumps 42% as EMR Integration Accelerates Community Penetration
August 06, 2025
22
Adaptive Biotechnologies (ADPT) Q1 2025: ClonoSeq Volume Climbs 36% as EMR Integrations Accelerate
July 04, 2025
Adaptive Biotechnologies (ADPT) Q3 2024: MRD Revenue Jumps 52% as ASP and Pharma Momentum Accelerate
November 07, 2024
Adaptive Biotechnologies (ADPT) Q2 2024: MRD Revenue Up 36% as Pharma Bookings and Cost Discipline Reshape Trajectory
August 01, 2024
Adaptive Biotechnologies (ADPT) Q1 2024: MRD Revenue Jumps 52% as FDA, Pricing Tailwinds Build
May 07, 2024
Adaptive Biotechnologies (ADPT) Q4 2023: MRD Clinical Revenue Jumps 56%, Margin Levers Set for 2025 Profitability
February 14, 2024
Adaptive Biotechnologies (ADPT) Q3 2023: MRD Clinical Volumes Up 56%, Strategic Review Signals Business Split
November 09, 2023
Adaptive Biotechnologies (ADPT) Q2 2023: ClonoSeq Test Volumes Up 52% as MRD Penetration Accelerates
August 02, 2023
Adaptive Biotechnologies (ADPT) Q1 2023: MRD Test Volume Surges 57%, Fueling Back-Half Growth Setup
May 03, 2023

Browse all companies